LNTH: Ascending Triangle detected on 16 Sep 2026

LNTH is forming an ascending triangle pattern with tight structure (score: 10.0) and strong volume confirmation (score: 10.0). The stock sits at $100.73, consolidating between key support at $100.86 and resistance at $104.95. The breakout score of 7.5 reflects moderate directional conviction off this base. RSI at 47.81 is neutral, and MACD histogram is positive at 0.0703. Current volume of 1.13M shares trails the 20-day average slightly (0.93 ratio), requiring volume acceleration on a push above resistance. The measured move target is $104.79, implying a 4.0% upside within the triangle structure.

Curium US LLC entered into a definitive agreement to acquire Lantheus Holdings for $7 billion on August 3, 2026. Analysts have adjusted fair value estimates to about $107 per share, citing updated deal terms around Curium's proposed $102.50 cash offer plus up to $12 in contingent value rights. Most recently, Lantheus reported Q2 2026 earnings on August 6, 2026, posting EPS of $1.55, exceeding analyst expectations of $1.26 by 23%. An image generated using investigational LNTH-2513 was selected as SNMMI's Image of the Year at the 2026 Society of Nuclear Medicine annual meeting, showing high diagnostic accuracy for detecting deep vein thrombosis. The merger announcement and strong earnings beat provide fundamental support for consolidation, while the pending deal creates a price floor near offer levels.

A successful breakout above $104.95 resistance would target the conservative measure of $104.79, though the pattern geometry suggests potential extension toward the $107 analyst price target tied to deal valuation. Volume must exceed the 1.22M 20-day average to confirm breakout conviction. The invalidation level sits at key support of $100.86; a break below this price would negate the triangle setup and suggest renewed selling. The 54.24% win probability reflects moderate statistical edge—better than a coin flip but not a high-confidence pattern. Time decay favors resolution within 2–4 weeks.

Q3 earnings are scheduled for November 5, 2026, introducing event risk into the pattern window. The pending acquisition itself creates binary risk: deal completion uncertainty, regulatory approval delays, or price adjustment would disrupt this technical setup. Beta of 0.32 indicates low systematic risk, but the overall market regime is bearish (score: -0.23), which conflicts with the healthcare sector's bullish regime (score: 0.11). Recent performance shows weakness: the stock is down 9.95% from its 52-week high and has declined 3.76% over three months. Volume is sub-par at 0.93x average, suggesting weak retail conviction. No elevated overbought condition (RSI at 47.81), but the pattern's 60.5 overall score—while structurally sound—leaves limited margin for error on a breakout.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.